Research programme: protein therapeutics - Ambrx/Pfizer

Drug Profile

Research programme: protein therapeutics - Ambrx/Pfizer

Latest Information Update: 21 May 2013

Price : $50

At a glance

  • Originator Ambrx; Wyeth
  • Developer Ambrx; Pfizer
  • Class Antibodies; Drug conjugates; Proteins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 21 May 2013 No development reported - Preclinical for Undefined indication in USA (Parenteral)
  • 15 Oct 2009 Wyeth has been acquired by Pfizer
  • 19 Sep 2009 Early research in Undefined indication in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top